Department of Cardiovascular Medicine, Fukuyama City Hospital, Fukuyama, Japan.
Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Cardiorenal Med. 2018;8(2):151-159. doi: 10.1159/000486971. Epub 2018 Mar 27.
Chronic kidney disease (CKD) and inflammation play critical roles in atherosclerosis. There is limited evidence regarding the relationship between CKD and patients receiving second-generation drug-eluting stents for coronary artery disease.
This study aimed to investigate the effect of CKD on cardiovascular and renal events in patients undergoing percutaneous coronary intervention (PCI) with everolimus-eluting stents (EES).
We analyzed 504 consecutive patients with stable angina pectoris and significant coronary artery stenosis treated with EES. CKD was defined as an estimated glomerular filtration rate < 60 mL/min/1.73 m2 before coronary angiography. The primary outcome was the occurrence of major adverse renal and cardiovascular events (MARCE) including cardiac death, revascularization, heart failure, cerebral infarction, worsening renal function > 25% from baseline, and renal replacement therapy at 1 year.
Patients were divided into the a MARCE (n = 126) and a non-MARCE (n = 378) group. The incidence of CKD was 51% in all subjects (including those on hemodialysis) and was significantly higher in the MARCE group than in the non-MARCE group (p = 0.00001). Multivariate logistic regression analysis identified that CKD was independently associated with MARCE (adjusted odds ratio 2.03, 95% confidence interval 1.21-3.39, p = 0.007). Patients were divided into four groups based on CKD and C-reactive protein (CRP) level prior to initial coronary angiography. Cox proportional hazards analysis revealed that patients with CKD and high CRP (≥0.3 mg/dL) had the worst prognosis (hazard ratio 4.371, 95% confidence interval 2.634-7.252, p = 0.00001) compared to patients without CKD and with low CRP.
CKD combined with CRP predicted more clinical events in patients undergoing PCI with EES.
慢性肾脏病(CKD)和炎症在动脉粥样硬化中起着关键作用。关于 CKD 与接受第二代药物洗脱支架治疗冠心病的患者之间的关系,证据有限。
本研究旨在探讨 CKD 对接受依维莫司洗脱支架(EES)经皮冠状动脉介入治疗(PCI)患者心血管和肾脏事件的影响。
我们分析了 504 例接受 EES 治疗的稳定型心绞痛和严重冠状动脉狭窄患者。CKD 定义为冠状动脉造影前肾小球滤过率<60 mL/min/1.73 m2。主要终点是 1 年内发生主要不良肾脏和心血管事件(MARCE),包括心脏死亡、血运重建、心力衰竭、脑梗死、肾功能从基线恶化>25%和肾脏替代治疗。
患者分为 MARCE 组(n=126)和非 MARCE 组(n=378)。所有患者(包括血液透析患者)的 CKD 发生率为 51%,MARCE 组明显高于非 MARCE 组(p=0.00001)。多变量逻辑回归分析确定 CKD 与 MARCE 独立相关(调整优势比 2.03,95%置信区间 1.21-3.39,p=0.007)。根据初始冠状动脉造影前的 CKD 和 C 反应蛋白(CRP)水平将患者分为四组。Cox 比例风险分析显示,CKD 合并高 CRP(≥0.3 mg/dL)患者的预后最差(危险比 4.371,95%置信区间 2.634-7.252,p=0.00001),与无 CKD 且 CRP 较低的患者相比。
CKD 合并 CRP 预测 EES 治疗 PCI 患者的临床事件更多。